Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Sociedad Andaluza de Enfermedades Infecciosas
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Age older than 18 years
HIV-infected patients with compensated liver cirrhosis by HCV genotype 1 or 4 without previous virological response(\*) to a standard dose treatment of both drugs.
Women of child-bearing age: negative pregnancy test
Ability to understand and sign a written consent form
You may not be if
HCV genotypes different to 1 or 4
Acute or chronic hepatitis B infection (positivity for hepatitis B surface antigen or plasma DNA) or other concomitant causes of liver disease
Pregnancy or breast feeding.
Decompensated liver disease at baseline.
Neutropenia \<1000/uL, anemia \<100 g/L or thrombocytopenia \<20.000/uL.
Creatinine clearance \< 50 mL/min.
Concomitant treatment with immunomodulators or zidovudine, didanosine or stavudine.
Organ or bone marrow transplantation
Current alcoholism or iv drug abuse. Methadone is allowed.
Current neoplasm and/or anti-tumor chemotherapy or immunomodulators
Psychosis or uncontrolled clinical depression
Auto-immune disease, including auto-immune hepatitis
History of significant cardiovascular disease (NYHA III-IV) including but not limited to uncontrolled hypertension, angina pectoris, myocardial infarction, coronary artery surgery and congestive heart failure.
Thyroid dysfunction.
Clinically significant retinal abnormalities
Inability to understand and sign a written consent form
Clareo Health | Retreatment With High Doses of pegIFN Alfa-2a and Ribavirin of Previous Nonresponders HIV-coinfected Patients With Cirrhosis Due to HCV 1-4
